摘要
目的:探讨并研究纤溶系统与纤维蛋白原在不稳定型心绞痛(UA)患者发病中的临床价值。方法:对108例不稳定型心绞痛患者和42稳定型心绞痛(SA)患者体内纤溶酶原激活物抑制剂-1(PAI-1)、组织型纤溶酶原激活剂(t-PA)、纤维蛋白原(FIB)水平进行检测,并与20例正常对照者进行对照,探讨其临床意义。结果:UA患者体内PAI-1、FIB水平明显高于SA患者和正常对照者,UA患者中有心血管事件发生者也明显高于无心血管事件发生者;UA患者体内t-PA水平明显低于SA患者和正常对照者,UA患者中有心血管事件发生者也明显低于无心血管事件发生者。结论:UA患者纤溶系统功能异常和FIB水平升高程度较SA患者更加明显,并且UA患者的心血管事件发生可能与溶系统功能异常和FIB水平升高相关。
Objective： To study the clinical significance of fibrinolysis and fibrinogen （FIB） in unstable angina pactoris （UA） patients. Methods： Levels of plasmin plasminogen activator inhibitor-1 （PAI-1）, tissue-type plasminogen activator（t-PA）, fibrinogen（FIB）in 108 patients with unstable angina pactoris （UA）, 42 patients with stable angina pactoris（SA） were measured, and 20 normal cases as control group were analyzed in the same ways. Results： Levels of PAI-1, FIB in UA patients were significantly higher than in SA patients and in normal cases, those in UA patients with heart events were also significantly higher than those UA patients without heart events,especially in UP pateints having higher levels of FIB; Levels of t-PA in UA patients were significantly lower than in SA patients and in normal cases, those in UA patients with heart events were also significantly lower than those UA without heart events. Conclusion： The abnormal of fibrinolysis function and increase of FIB levels in US patients was more evident than that in SA patients, and the heart events in UA patients might be associated with the abnormal of fibrinolysis function and increase of FIB levels.
出处
《华西医学》
CAS
2009年第7期1719-1721,共3页
West China Medical Journal
作者简介
作者简介：梁振炼（1968-），男，海南文昌人，主治医师。
